Gujarat Themis Biosyn hits the roof on signing pact with Lupin

Gujarat Themis Biosyn hit an upper circuit limit of 5% at Rs 26.05 at 14:58 IST on BSE after the company said it signed a three-year pact to manufacture and supply finish products to Lupin.

The announcement was made during trading hours today, 10 February 2015.

Meanwhile, the BSE Sensex was up 134.53 points, or 0.48%, to 28,361.92.

On BSE, so far 70,000 shares were traded in the counter, compared with an average volume of 17,930 shares in the past one quarter.

The stock hit a low of Rs 23.65 in intraday trade. The stock hit a 52-week high of Rs 27.90 on 6 February 2015. The stock hit a 52-week low of Rs 9 on 15 May 2014.

The stock had outperformed the market over the past one month till 9 February 2015, rising 8.04% compared with 2.80% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 26.14% as against Sensex's 1.29% rise.

The small-cap company has an equity capital of Rs 7.26 crore. Face value per share is Rs 5.

Gujarat Themis Biosyn announced entering into an agreement for manufacturing and supplying finish products to Lupin on revised terms during the period 1 April 2015 to 31 March 2018.

Net profit of Gujarat Themis Biosyn rose 23.42% to Rs 1.37 crore on 7.93% rise in net sales to Rs 7.89 crore in Q3 December 2014 over Q3 December 2013.

Gujarat Themis Biosyn produces pharmaceutical ingredients like Rifamycin-S and Lovastatin.

Powered by Capital Market - Live News